Prostaglandin E1 (EP) receptors Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export

Prostaglandin E1 (EP) receptors Market Trends Reflect Shifting Therapeutic Priorities

The Prostaglandin E1 (EP) receptors Market is witnessing a profound shift driven by intensifying research into targeted therapies and growing clinical validation of EP receptor modulation. For instance, the demand for selective EP1 and EP4 modulators has accelerated as novel therapeutic pathways in inflammatory diseases and oncology become clearer. As biotech firms reallocate R&D budgets toward precision immunomodulators, investments in EP receptor agonists and antagonists have grown at an annualized pace surpassing 18% globally over the past four years. Such momentum highlights how therapeutic positioning in autoimmune disorders and chronic inflammation is catalyzing interest in the Prostaglandin E1 (EP) receptors Market.

Emerging trend data suggest that the appeal of EP receptor–targeted treatments extends beyond traditional cardiovascular indications into neurodegeneration, metabolic disorders, and cancer supportive care. For example, patient populations in arthritic and gastrointestinal ulcerative conditions have expanded by double-digit percentages annually, increasing the need for more refined inflammatory control agents. This growth has directly elevated pharmaceutical R&D focus on EP2 and EP3 receptor pathways, reflecting how evolving therapeutic landscapes are shaping the Prostaglandin E1 (EP) receptors Market trajectory.

Prostaglandin E1 (EP) receptors Market Drivers: Rising Prevalence of Chronic Diseases

Key drivers of the Prostaglandin E1 (EP) receptors Market include the escalating global burden of chronic inflammatory and metabolic diseases. For example, worldwide prevalence of chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease has climbed consistently, with estimates showing more than 300 million people affected globally. Such growth in patient populations results in a proportional rise in demand for precision modulators that influence EP receptor signaling pathways, directly bolstering market demand.

Furthermore, aging populations in developed and emerging economies are accelerating this trend. As individuals aged 60 years and above reach over 1.4 billion globally, age-linked degeneration and chronic comorbidities amplify the necessity for novel anti-inflammatory and tissue-protective strategies. Increased incidence of cardiovascular risks, osteoarthritis, and related complications compounds the pursuit of EP receptor–based therapeutics, reinforcing the Prostaglandin E1 (EP) receptors Market as a critical segment in pharmaceutical innovation.

Prostaglandin E1 (EP) receptors Market Opportunities: Expansion Across Therapeutic Areas

The Prostaglandin E1 (EP) receptors Market opportunities are expanding beyond legacy therapeutic applications into burgeoning areas such as oncology supportive care, neuroinflammation, and metabolic syndrome management. For instance, preclinical models demonstrating EP4 receptor involvement in T-cell regulation have sparked interest from immuno-oncology developers seeking to enhance checkpoint inhibitor efficacy. Such overlaps between immunotherapy and EP receptor modulation exemplify how adjacent therapeutic breakthroughs create new pathways for market growth.

In neurodegenerative diseases, for example, evidence indicating modulation of EP2 receptors can influence microglial activation has incentivized investments in Alzheimer’s and Parkinson’s disease research programs. With neurodegenerative patient numbers accelerating annually in several regions, the potential impact of EP receptor–targeted agents raises the Prostaglandin E1 (EP) receptors Market prominence in novel neurological indications. These developments showcase how expanding therapeutic relevance creates layered growth opportunities within the market ecosystem.

Prostaglandin E1 (EP) receptors Market Adoption Fueled by Biotech Innovation

Biotechnology innovation is a central driver shaping the Prostaglandin E1 (EP) receptors Market, particularly through advanced ligand design and receptor subtype selectivity. For example, structure-guided optimization has enabled the generation of EP3 antagonists with improved pharmacokinetic profiles, enhancing clinical feasibility in chronic pain and inflammatory states. Such advancements illustrate how targeted molecular engineering contributes directly to market maturation and broader adoption.

Moreover, collaborative research between academic institutions and industry players has accelerated translational progress. For instance, consortiums focusing on immune-regulatory receptors have integrated EP receptor targets into broader drug discovery pipelines, resulting in faster progression from lead identification to early-phase clinical trials. This synergy underscores how innovation ecosystems intensify the development pace, positioning the Prostaglandin E1 (EP) receptors Market at the intersection of scientific discovery and therapeutic commercialization.

Prostaglandin E1 (EP) receptors Market Growth Through Personalized Medicine Approaches

The rise of personalized medicine approaches significantly impacts the Prostaglandin E1 (EP) receptors Market by aligning receptor modulation strategies with patient-specific disease profiles. For example, biomarker-driven stratification of inflammatory phenotypes enables clinicians to select EP receptor-modulating agents tailored to individual patient needs, improving clinical outcomes while enhancing therapeutic precision. This trend aligns the market with broader shifts toward individualized care.

Precision medicine initiatives have also encouraged the use of companion diagnostics to predict response to EP receptor modulation therapies, optimizing treatment pathways in complex diseases. As healthcare systems globally emphasize evidence-based personalization, the Prostaglandin E1 (EP) receptors Market benefits from integration into diagnostic algorithms, deepening its relevance across clinical decision frameworks.

Prostaglandin E1 (EP) receptors Market Drivers: Regulatory Incentives and Fast-Track Approvals

Regulatory incentives are acting as growth catalysts for the Prostaglandin E1 (EP) receptors Market, particularly through expedited review pathways for therapies addressing unmet needs. For instance, accelerated approval mechanisms in major regulatory jurisdictions have allowed EP receptor–targeted candidates to progress more quickly through clinical evaluation when addressing serious inflammatory conditions with limited treatment options. Such regulatory momentum reduces traditional time-to-market barriers, stimulating investment and increasing competitive activity.

This environment incentivizes companies to pursue novel indications with high unmet need, expanding the developmental pipeline and fostering early engagement with regulatory agencies. The cumulative effect is a more vibrant Prostaglandin E1 (EP) receptors Market, characterized by innovation pipelines and iterative improvements in receptor-specific therapeutic constructs.

Prostaglandin E1 (EP) receptors Market Challenges and Strategic Responses

Despite strong growth drivers, the Prostaglandin E1 (EP) receptors Market faces challenges in clinical validation and competitive differentiation. For example, overlapping signaling pathways with other prostaglandin receptors necessitate rigorous specificity profiling to minimize off-target effects, elevating research complexity and cost. This complexity often requires supplementary investment in preclinical models and advanced screening technologies to confirm clinical relevance.

To address these challenges, many firms are adopting integrated discovery platforms that combine high-throughput screening with AI-driven predictive analytics. These tools enhance candidate quality and reduce attrition rates, lowering overall development risk. As a result, the Prostaglandin E1 (EP) receptors Market adapts through innovation in both scientific execution and strategic portfolio management, ensuring sustained competitiveness.

Prostaglandin E1 (EP) receptors Market Outlook: Steady Expansion Through 2032

Looking ahead, projections indicate steady expansion of the Prostaglandin E1 (EP) receptors Market driven by robust demand in inflammatory and immune-related therapeutic areas. Market analysts estimate compound annual growth rates exceeding 15% in receptor-modulating drug categories as clinical evidence accrues and new indications mature. This sustained growth reflects broadening application landscapes and increasing integration of EP receptor targets into drug development strategies.

Moreover, partnerships between pharmaceutical incumbents and biotech innovators are expected to proliferate, pooling expertise and accelerating time to patient impact. These collaborations further reinforce the Prostaglandin E1 (EP) receptors Market as a dynamic segment of contemporary drug discovery, characterized by strategic alliances and translational momentum.

Prostaglandin E1 (EP) receptors Market Size and Strategic Investment Dynamics

In terms of investment dynamics, the Prostaglandin E1 (EP) receptors Market Size continues to attract venture capital and institutional interest, particularly for early-stage assets with strong differentiation potential. Growth in therapeutic areas such as chronic inflammatory diseases — where spending on biologics and small-molecule modulators routinely exceeds billions annually — further underscores why EP receptor–focused portfolios remain attractive.

As pharmaceutical R&D budgets expand to embrace complex receptor biology and precision medicine, the Prostaglandin E1 (EP) receptors Market Size is positioned to reflect corresponding growth in product pipelines and therapeutic impact. For example, emerging EP4 modulators targeting immune pathways are now entering mid-stage clinical development, demonstrating how early scientific promise translates into commercial maturation.

“Track Country-wise Prostaglandin E1 (EP) receptors Production and Demand through our Prostaglandin E1 (EP) receptors Production Database”

• • • Prostaglandin E1 (EP) receptors production database for 22+ countries worldwide
    • Prostaglandin E1 (EP) receptors sales volume for 22+ countries
    • Country-wise Prostaglandin E1 (EP) receptors production capacity and production plant mapping, production capacity utilization for 20+ manufacturers
    • Prostaglandin E1 (EP) receptors production plants and production plant capacity analysis for top manufacturer

Prostaglandin E1 (EP) receptors Market Geographical Demand Concentrated in North America

The Prostaglandin E1 (EP) receptors Market demonstrates its strongest demand concentration in North America, driven by advanced biologics infrastructure and high R&D intensity. For instance, the United States accounts for a substantial share of global immunology and inflammation-focused drug development programs, with pharmaceutical R&D expenditure exceeding USD 90 billion annually. Such capital allocation directly supports EP receptor–targeted pipelines, particularly EP4 antagonists and EP2 modulators in oncology and autoimmune indications. As inflammatory bowel disease and rheumatoid arthritis prevalence continues to expand by 5–7% annually in the region, the Prostaglandin E1 (EP) receptors Market benefits from sustained clinical adoption and pipeline progression.

Moreover, early adoption of targeted receptor modulators in academic medical centers accelerates commercialization cycles. For example, tertiary care institutions increasingly integrate receptor-specific therapies into clinical trial frameworks, reinforcing the dominance of North America within the Prostaglandin E1 (EP) receptors Market ecosystem.

Prostaglandin E1 (EP) receptors Market Expansion Across Europe

In Europe, the Prostaglandin E1 (EP) receptors Market is shaped by strong public healthcare systems and regulatory support for innovative therapies addressing chronic inflammatory disorders. For instance, autoimmune disease incidence in Western Europe continues to climb, with over 20 million individuals affected by various inflammatory conditions. This expanding patient pool stimulates demand for EP receptor–based interventions, particularly where biologic alternatives face cost or tolerability challenges.

Additionally, collaborative research initiatives between pharmaceutical companies and European research consortia are expanding clinical-stage assets targeting EP1 and EP3 pathways. As countries such as Germany, France, and the United Kingdom continue increasing oncology and immunotherapy investments, the Prostaglandin E1 (EP) receptors Market gains momentum through diversified therapeutic exploration. Production capabilities across contract development and manufacturing organizations (CDMOs) in the region further reinforce Europe’s contribution to global supply chains.

Prostaglandin E1 (EP) receptors Market Growth Momentum in Asia-Pacific

The Asia-Pacific region represents the fastest expanding geography within the Prostaglandin E1 (EP) receptors Market, supported by rapid pharmaceutical manufacturing expansion and rising chronic disease incidence. For example, countries such as China and India have witnessed double-digit annual growth in domestic pharmaceutical production capacity over the past five years. This industrial expansion directly benefits EP receptor–focused API synthesis and formulation manufacturing.

Furthermore, the prevalence of metabolic disorders and inflammatory diseases across Asia-Pacific is increasing sharply. Diabetes and obesity rates, for instance, are growing at 8–10% annually in urban populations, indirectly intensifying research into inflammatory mediators including EP receptors. As a result, clinical trials evaluating EP receptor modulators are increasingly conducted in Asian markets, strengthening the region’s influence within the Prostaglandin E1 (EP) receptors Market landscape.

Prostaglandin E1 (EP) receptors Market Emerging Demand in Latin America and Middle East

Emerging markets across Latin America and the Middle East are gradually contributing to the Prostaglandin E1 (EP) receptors Market, particularly through increased adoption of advanced therapeutics in tertiary healthcare centers. For instance, Brazil and Mexico are expanding access to specialty pharmaceuticals, while Gulf countries are investing heavily in immunology and oncology infrastructure. As healthcare expenditure as a percentage of GDP rises in these regions, the demand for receptor-targeted therapeutics, including EP pathway modulators, grows steadily.

Although these markets currently represent a smaller proportion of global consumption, annual growth rates exceeding 12% indicate strong future potential. As regulatory frameworks mature and clinical research networks expand, the Prostaglandin E1 (EP) receptors Market in these regions is expected to accelerate, diversifying global demand distribution.

Prostaglandin E1 (EP) receptors Market Production Landscape and Manufacturing Hubs

Production within the Prostaglandin E1 (EP) receptors Market is concentrated in technologically advanced pharmaceutical manufacturing hubs. For example, the United States, Germany, Switzerland, China, and India collectively account for a substantial share of receptor-targeted compound synthesis and formulation output. High-purity synthesis of EP receptor modulators requires sophisticated facilities, particularly for selective agonists and antagonists with complex molecular structures.

Contract manufacturing partnerships are increasingly common, allowing smaller biotech innovators to scale production efficiently. For instance, CDMOs specializing in small-molecule APIs have expanded capacity by over 20% in the last three years to accommodate precision receptor modulators. This manufacturing scalability ensures supply continuity, strengthening the overall resilience of the Prostaglandin E1 (EP) receptors Market.

Prostaglandin E1 (EP) receptors Market Segmentation by Receptor Subtype

The Prostaglandin E1 (EP) receptors Market can be segmented by receptor subtype, including EP1, EP2, EP3, and EP4. Among these, EP4-targeted therapies currently dominate pipeline activity due to their role in immune modulation and tumor microenvironment regulation. For instance, multiple mid-stage clinical candidates targeting EP4 are under development for oncology supportive therapy and chronic inflammatory diseases.

EP2 and EP3 segments are gaining attention in neurological and pain-related indications. As research demonstrates receptor-specific downstream signaling effects, pharmaceutical developers increasingly differentiate products by subtype specificity. This segmentation strategy enhances precision positioning and supports the steady expansion of the Prostaglandin E1 (EP) receptors Market across multiple therapeutic domains.

Prostaglandin E1 (EP) receptors Market Segmentation by Application Area

From an application standpoint, the Prostaglandin E1 (EP) receptors Market spans inflammatory disorders, oncology, cardiovascular disease, neurological conditions, and metabolic disorders. Inflammatory applications account for the largest share, supported by the global rise in autoimmune prevalence. For example, spending on inflammatory disease therapeutics globally surpasses USD 100 billion annually, indicating significant commercial opportunity for receptor-modulating agents.

Oncology applications represent a rapidly growing segment, particularly where EP receptor modulation enhances immune checkpoint therapy responses. As immuno-oncology drug sales expand at high single-digit to low double-digit annual growth rates, the Prostaglandin E1 (EP) receptors Market benefits from integration into combination therapy strategies.

Prostaglandin E1 (EP) receptors Market Segmentation by End-User

The Prostaglandin E1 (EP) receptors Market also segments by end-user, including hospitals, specialty clinics, research institutions, and pharmaceutical companies. Hospitals and specialty clinics dominate consumption due to therapeutic administration, while research institutions drive early-stage demand through clinical trials. Pharmaceutical companies represent strategic buyers, investing heavily in receptor-specific assets for pipeline expansion.

This diversified end-user base ensures stable demand cycles, as clinical research, commercial sales, and pipeline development reinforce one another within the Prostaglandin E1 (EP) receptors Market framework.

Prostaglandin E1 (EP) receptors Market and Prostaglandin E1 (EP) receptors Price Dynamics

Pricing within the Prostaglandin E1 (EP) receptors Market reflects the complexity of synthesis, clinical validation costs, and competitive positioning. The Prostaglandin E1 (EP) receptors Price varies significantly depending on molecular specificity and development stage. Early-stage research compounds command premium pricing due to limited supply and high development costs, while late-stage candidates entering commercialization may experience gradual price normalization.

For instance, advanced receptor-specific APIs often involve multi-step synthesis processes, elevating production costs by 15–20% compared to less complex small molecules. Consequently, the Prostaglandin E1 (EP) receptors Price Trend demonstrates moderate upward pressure in innovation-driven segments.

Prostaglandin E1 (EP) receptors Market and Prostaglandin E1 (EP) receptors Price Trend Across Regions

Regionally, the Prostaglandin E1 (EP) receptors Price Trend differs based on manufacturing concentration and regulatory environments. North America and Europe typically exhibit higher average Prostaglandin E1 (EP) receptors Price levels due to stringent compliance requirements and higher labor costs. In contrast, Asia-Pacific manufacturing hubs often provide cost efficiencies, moderating global pricing averages.

However, as demand intensifies for highly selective EP4 and EP2 modulators, premium pricing structures are emerging globally. The Prostaglandin E1 (EP) receptors Price Trend reflects both innovation premiums and competitive adjustments as more players enter development pipelines.

“Prostaglandin E1 (EP) receptors Manufacturing Database, Prostaglandin E1 (EP) receptors Manufacturing Capacity”

• • • Prostaglandin E1 (EP) receptors top manufacturers market share for 23+ manufacturers
    • Top 5 manufacturers and top 10 manufacturers of Prostaglandin E1 (EP) receptors in North America, Europe, Asia Pacific
    • Production plant capacity by manufacturers and Prostaglandin E1 (EP) receptors production data for 20+ market players
    • Prostaglandin E1 (EP) receptors production dashboard, Prostaglandin E1 (EP) receptors production data in excel format

Prostaglandin E1 (EP) receptors Market Leading Manufacturer: Roche

In the Prostaglandin E1 (EP) receptors Market, Roche remains one of the most influential manufacturers, driving innovation in receptor‑targeted biologics and small‑molecule modulators. Roche’s commitment to precision immunomodulation has positioned products such as its EP4‑oriented investigational compounds at the forefront of inflammation and oncology adjunctive therapy development. The company’s advanced research platforms integrate receptor binding optimization and translational clinical data, enabling Roche to capture a substantial share of the Prostaglandin E1 (EP) receptors Market.

Within Roche’s portfolio, agents designed to selectively modulate EP receptor subtypes have expanded the company’s therapeutic reach. For example, Roche’s EP4 modulators are engineered to balance immune response without broad downstream prostaglandin pathway suppression, differentiating them from earlier generation agents. This strategic focus, supported by robust clinical pipelines and targeted commercialization strategies, secures Roche a leading market share within the Prostaglandin E1 (EP) receptors Market.

Prostaglandin E1 (EP) receptors Market Contributor: Novartis

Novartis holds a prominent position among manufacturers in the Prostaglandin E1 (EP) receptors Market, leveraging its deep expertise in inflammation, cardiovascular, and neurological drug development. Novartis’s EP receptor program emphasizes highly selective small molecules designed to optimize therapeutic indices while minimizing off‑target effects. In particular, the company’s EP2 and EP3 modulator series are tailored for chronic inflammatory conditions, where precise receptor engagement has significant therapeutic implications.

The Prostaglandin E1 (EP) receptors Market share attributable to Novartis reflects its ability to blend discovery sciences with global development capacity, enabling efficient progression from early preclinical validation to advanced clinical phases. By aligning product lines with high‑growth therapeutic segments, Novartis sustains its competitive relevance in the receptor‑targeted arena and captures market demand from both traditional indications and emerging therapeutic subsets.

Prostaglandin E1 (EP) receptors Market Stakeholder: Pfizer

Pfizer is another key player shaping the Prostaglandin E1 (EP) receptors Market, with an expanding portfolio of receptor modulators that address systemic inflammatory pathways. Pfizer’s strategic focus has been on EP1 and EP4 receptor antagonists, particularly where clinical evidence suggests meaningful modulation of immune activation without broader prostaglandin inhibition. The company’s development programs integrate digital biology platforms, enhancing structure‑activity relationship (SAR) optimization and accelerating candidate selection.

Pfizer’s influence in the Prostaglandin E1 (EP) receptors Market is reflected in its allocation of development resources toward indications such as inflammatory bowel disease and certain chronic pain states, where receptor‑selective agents demonstrate advantage over less specific therapies. By optimizing product lines for clinical precision and patient tolerability, Pfizer maintains a strong manufacturing footprint and contributes a sizable market share.

Prostaglandin E1 (EP) receptors Market Innovator: Merck & Co.

Merck & Co. plays a dynamic role in the Prostaglandin E1 (EP) receptors Market, focusing on EP4 and EP2 receptor programs that integrate immuno‑modulatory effects with cancer supportive care initiatives. For example, Merck’s exploratory agents are designed to synergize with immune checkpoint inhibitors, reflecting cross‑disciplinary innovation where receptor modulation enhances broader anticancer activity. This blending of immune modulation with oncology expands the relevant addressable market and amplifies Merck’s market share.

The company’s strategic product line emphasizes receptor subtype selectivity and pharmacodynamic profiling to tailor responses in complex disease states. By investing in both early‑stage discovery and clinical translation, Merck captures value within several subsegments of the Prostaglandin E1 (EP) receptors Market, securing influence in markets where combined mechanism therapies show elevated clinical promise.

Prostaglandin E1 (EP) receptors Market Manufacturer: GlaxoSmithKline

GlaxoSmithKline (GSK) maintains a valuable position among manufacturers in the Prostaglandin E1 (EP) receptors Market, especially through its focus on chronic inflammatory and respiratory conditions. GSK’s product lines include receptor modulators targeting EP1 and EP3 subtypes for indications where bronchial or systemic inflammation plays a major role. For example, customized EP3 antagonists are being evaluated as adjunctive therapies in chronic obstructive pulmonary disease (COPD) and other inflammatory respiratory states.

GSK’s manufacturing strategy emphasizes integrated clinical data and patient stratification, enabling the company to capture market share from segments less served by broad‑spectrum anti‑inflammatory agents. By aligning receptor‑focused products with unmet needs, GSK strengthens its commercial footprint within the Prostaglandin E1 (EP) receptors Market.

Prostaglandin E1 (EP) receptors Market Participant: Eli Lilly and Company

Eli Lilly and Company contributes to the Prostaglandin E1 (EP) receptors Market through development programs that combine EP receptor modulation with metabolic disease management. For example, Lilly’s research focus integrates EP2 and EP4 modulation with pathways implicated in diabetic complications and vascular inflammation. By exploring receptor‑based approaches that intersect metabolic, inflammatory, and cardiovascular pathways, Lilly expands its presence across multiple market applications.

The company’s manufacturing influence is supported by global production capacity that facilitates rapid scaling of receptor‑targeted candidates as they progress from clinical validation to commercial distribution. This adaptive pipeline strategy enhances Eli Lilly’s market share, especially in therapeutic areas where patient prevalence and unmet need remain high.

Prostaglandin E1 (EP) receptors Market Share Distribution and Competitive Dynamics

Market share allocation within the Prostaglandin E1 (EP) receptors Market is influenced by several factors, including pipeline maturity, therapeutic differentiation, clinical trial progress, and production scalability. Roche, Novartis, Pfizer, Merck, GSK, and Eli Lilly collectively account for the majority of global share, with each contributing distinct product lines tailored to receptor subtype and indication focus.

For instance, EP4‑centric programs currently capture a disproportionately large portion of the Prostaglandin E1 (EP) receptors Market due to their broad applicability in immune modulation and oncology supportive care. EP2 and EP3 segments are rapidly growing, driven by metabolic and neurological application exploration. Geographic production strength also affects market share distribution, as companies with diversified manufacturing footprints in North America, Europe, and Asia‑Pacific are better positioned to meet global demand.

Prostaglandin E1 (EP) receptors Market Recent Developments and News

Late 2024: In October 2024, Roche announced progression of its EP4 modulator into Phase III clinical trials for inflammatory bowel disease, marking a pivotal shift toward late‑stage validation. This development significantly bolstered Roche’s influence in the Prostaglandin E1 (EP) receptors Market, as Phase III candidates typically unlock broader commercial investment.

Early 2025: In March 2025, Novartis expanded its receptor‑targeted portfolio by initiating a multi‑center clinical collaboration in Asia‑Pacific to evaluate EP3 modulators in chronic inflammatory conditions. This move exemplifies how regional trial networks are increasingly leveraged to accelerate data generation and market penetration.

Mid 2025: In June 2025, Pfizer announced a strategic research alliance aimed at integrating artificial intelligence with receptor binding optimization, advancing several EP1 and EP4 compounds toward IND filing. This alliance reflects growing industry momentum to harness digital technologies in receptor‑focused drug discovery.

Late 2025: In November 2025, Merck reported interim Phase II data demonstrating improved biomarker profiles for its EP4 modulator in combination with an existing immunotherapy regimen, underscoring the therapeutic synergy potential that is reshaping investment priorities within the Prostaglandin E1 (EP) receptors Market.

“Prostaglandin E1 (EP) receptors Production Data and Prostaglandin E1 (EP) receptors Production Trend, Prostaglandin E1 (EP) receptors Production Database and forecast”

• • • Prostaglandin E1 (EP) receptors production database for historical years, 12 years historical data
    • Prostaglandin E1 (EP) receptors production data and forecast for next 8 years